Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Localized Lipodystrophy Treatment & Management

  • Author: Serhat Aytug, MD; Chief Editor: George T Griffing, MD  more...
 
Updated: Dec 16, 2014
 

Medical Care

No specific medical treatment exists.[12]

Treatment of insulin lipodystrophy consists of reassuring the patient that the condition is benign, switching to purified insulin (pork or human), and having the patient inject insulin in noninvolved areas and rotate the injection sites. This regimen is effective in more than 95% of patients. Improvement begins in 2-4 weeks, and normal consistency generally is restored within 2 months.

Treatment of underlying immunological disorders might prevent progression of the disease.

Next

Surgical Care

Surgical treatment with adipofascial flaps has been successful in some cases.

Previous
Next

Consultations

Dermatological, medical, and surgical consultations are appropriate.

Previous
Next

Diet

No specific dietary recommendations or restriction of diet has been recommended.

Previous
Next

Activity

No specific activity or restriction of activity has been proposed.

Previous
 
 
Contributor Information and Disclosures
Author

Serhat Aytug, MD Endocrinologist, Division of Endocrinology, Diabetes and Metabolism, St Jude Heritage Medical Group

Serhat Aytug, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Nutrition, American Society for Bone and Mineral Research, International Society for Clinical Densitometry, American College of Endocrinology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Informatics Association, Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

David M Klachko, MD, MEd Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Missouri-Columbia School of Medicine

David M Klachko, MD, MEd is a member of the following medical societies: Alpha Omega Alpha, Missouri State Medical Association, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Federation for Medical Research, Endocrine Society, Sigma Xi

Disclosure: Nothing to disclose.

Acknowledgements

Rubens Sievert, MD Clinical Assistant Professor, Department of Internal Medicine, Mount Sinai School of Medicine

Rubens Sievert, MD is a member of the following medical societies: American Thyroid Association

Disclosure: Nothing to disclose.

References
  1. Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011 Nov. 96(11):3313-25. [Medline].

  2. Touraine P, D'Souza GA, Kourides I, et al. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol. 2009 Oct. 161(4):533-40. [Medline].

  3. Winkelmann RK, Padilha-Goncalves A. Connective tissue panniculitis. Arch Dermatol. 1980 Mar. 116(3):291-4. [Medline].

  4. Gdynia HJ, Weydt P, Ernst A, et al. Myositis associated with localized lipodystrophy: an unrecognized condition?. Eur J Med Res. 2009 May 14. 14(5):228-30. [Medline].

  5. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014 Jan. 59(1):16-23. [Medline].

  6. Hisamichi K, Suga Y, Hashimoto Y, Matsuba S, Mizoguchi M, Ogawa H. Two Japanese cases of localized involutional lipoatrophy. Int J Dermatol. 2002 Mar. 41(3):176-7. [Medline].

  7. Yamamoto T, Yokozeki H, Nishioka K. Localized involutional lipoatrophy: report of six cases. J Dermatol. 2002 Oct. 29(10):638-43. [Medline].

  8. Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol. 2004. 5(5):357-9. [Medline].

  9. Peteiro-Gonzalez D, Fernandez-Rodriguez B, Cabezas-Agricola JM, Araujo-Vilar D. Severe localized lipoatrophy related to therapy with insulin analogs in type 1a diabetes mellitus. Diabetes Res Clin Pract. 2011 Mar. 91(3):e61-3. [Medline].

  10. Winkelmann RK, Frigas E. Eosinophilic panniculitis: a clinicopathologic study. J Cutan Pathol. 1986 Feb. 13(1):1-12. [Medline].

  11. Winkelmann RK. [Panniculitis with cellular phagocytosis. Chronic form of histiocytic panniculitis with fever, pancytopenia, polyserositis and lethal hemorrhagic diathesis]. Hautarzt. 1980 Nov. 31(11):588-94. [Medline].

  12. Gassling VL, Douglas T, Wiltfang J, et al. Unilateral atrophy of the cheek: autologous fat injection as treatment of choice. J Craniofac Surg. 2009 Mar. 20(2):423-5. [Medline].

  13. Buyukgebiz A, Aydin A, Dundar B, Yorukoglu K. Localized lipoatrophy due to recombinant growth hormone therapy in a child with 6.7 kilobase gene deletion isolated growth hormone deficiency. J Pediatr Endocrinol Metab. 1999 Jan-Feb. 12(1):95-7. [Medline].

  14. Capanni C, Mattioli E, Columbaro M, Lucarelli E, Parnaik VK, Novelli G, et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet. 2005 Jun 1. 14(11):1489-502. [Medline].

  15. Drago F, Rongioletti F, Battifoglio ML, Rebora A. Localised lipoatrophy after acupuncture. Lancet. 1996 May 25. 347(9013):1484. [Medline].

  16. Koshy CE, Evans J. Facial contour reconstruction in localised lipodystrophy using free radial forearm adipofascial flaps. Br J Plast Surg. 1998 Oct. 51(7):499-502. [Medline].

  17. Peters MS, Winkelmann RK. Localized lipoatrophy (atrophic connective tissue disease panniculitis). Arch Dermatol. 1980 Dec. 116(12):1363-8. [Medline].

  18. Peters MS, Winkelmann RK. The histopathology of localized lipoatrophy. Br J Dermatol. 1986 Jan. 114(1):27-36. [Medline].

  19. Serrao VV, Feio AB. Localized abdominal idiopathic lipodystrophy. Dermatol Online J. 2008 Jul 15. 14(7):15. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.